Publication

研究業績

2006年

  1. X.Y. Gao, K. Nishimura, F. Hirayama, H. Arima, K. Uekama, G. Schmid, K. Terao, D. Nakata, H. Fukumi,
    Enhanced Dissolution and Bioavailability of Coenzyme Q10 in Dogs Obtained by Inclusion Complexation with γ-Cyclodextrin,
    Asian J. Pharm. Sci., 1 (2), 95-102 (2006).
  2. K. Anzai, H. Kono, J.I. Mizoguchi, T. Yanagi, F. Hirayama, H. Arima, K. Uekama,
    Two-dimensional 13C-1H Heteronuclear Correlation NMR Spectroscopic Studies for the Inclusion Complex of Cyclomaltoheptaose (β-Cyclodextrin) with a New Helicobacter Pylori Eradicating Agent (TG44) in the Amorphous State,
    Carbohydr. Res., 341 (4), 499-506 (2006).
  3. Y. Sonoda, F. Hirayama, H. Arima, Y. Yamaguchi, W. Saenger, K. Uekama,
    Cyclodextrin-based Isolation of Ostwald’s Metastable Polymorphs Occurring during Crystallization,
    Chem. Commun., 2006 (5), 517-519 (2006). Selected as a hot article.
  4. Y. Hagiwara, H. Arima, Y. Miyamoto, F. Hirayama, K. Uekama,
    Preparation and Pharmaceutical Evaluation of Liposomes Entrapping Salicylic Acid/γ-Cyclodextrin Conjugate,
    Chem. Pharm. Bull., 54 (1), 26-32 (2006).
  5. T. Hara, F. Hirayama, H. Arima, Y. Yamaguchi, K. Uekama,
    Improvement of Solubility and Oral Bioavailability of 2-(N-Cyanoimino)-5-{(E)-4- styrylbenzylidene}-4-oxothiazolidine (FPFS-410) with Antidiabetic and Lipid-lowering Activities in Dogs by 2-Hydroxypropyl-β-cyclodextrin,
    Chem. Pharm. Bull., 54 (3), 344-349 (2006). Selected as a journal cover of issue 3.
  6. T. Hara, H. Arima, F. Hirayama, K. Uekama,
    Enhanced Bioavailability of a New Thiazolidine Derivative FPFS-410, an Antidiabetic and Lipid-lowering Drug, after Oral Administration of Its Hydroxypropyl-β-cyclodextrin Complex to Bile Duct-cannulated Rats,
    J. Pharm. Sci., 95, 1771-1782 (2006).
  7. Y. Sonoda, F. Hirayama, H. Arima, Y. Yamaguchi, W. Saenger, K. Uekama,
    Selective Crystallization of the Metastable Form IV Polymorph of Tolbutamide in the Presence of 2,6-Di-O-methyl-β-cyclodextrin in Aqueous Solution,
    Crystal Growth ＆ Design, 6 (5), 1181-1185 (2006).
  8. K. Motoyama, H. Arima, H. Toyodome, T. Irie, F. Hirayama, K. Uekama,
    Effect of 2,6-Di-O-methyl-α-cyclodextrin on Hemolysis and Morphological Changes in Rabbit’s Red Blood Cells,
    Eur. J. Pharm. Sci.,29 , 111-119 (2006),
  9. H. Arima, Y. Chihara, M. Arizono, S. Yamashita, K. Wada, F. Hirayama, K. Uekama,
    Enhancement of Gene Transfer Activity Mediated by Mannosylated Dendrimer/α-Cyclodextrin Conjugate (Generation 3, G3),
    J. Control. Release, 116 (1), 64-74 (2006).
  10. H. Arima, Y. Hagiwara, F. Hirayama, K. Uekama,
    Enhancement of Antitumor Effect of Doxorubcin by Its Complexation with γ-Cyclodextrin in Pegylated Liposomes,
    J. Drug Targeting, 14 (4), 225-232 (2006).
  11. Y. Hagiwara, H. Arima, F. Hirayama, K. Uekama,
    Prolonged Retention of Doxorubicin in Tumor Cells by Encapsulation of γ-Cyclodextrin Complex in Pegylated Liposomes,
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 65-68 (2006).
  12. K. Motoyama, H. Arima, F. Hirayama, K. Uekama,
    Inhibitory Effects of 2,6-Di-O-methyl-3-O-acetyl-β-cyclodextrins with Various Degrees of Substitution of Acetyl Group on Macrophage Activation and Endotoxin Shock Induced by Lipopolysaccharide,
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 75-79 (2006).
  13. T. Tsutsumi, H. Arima, F. Hirayama, K. Uekama,
    Potential Use of Dendrimer/α-Cyclodextrin Conjugate as a Novel Carrier for Small Interfering RNA (siRNA),
    J. Incl. Phenom. Macrocycl. Chem. , 56 (1-2), 81-84 (2006).
  14. K. Nishimura, R. Hidaka, F. Hirayama, H. Arima, K. Uekama,
    Improvement of Dispersion and Release Properties of Nifedipine in Suppositories by Complexation with 2-Hydroxypropyl-β-cyclodextrin,
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 85-88 (2006).
  15. Y. Chihara, H. Arima, M. Arizono, K. Wada, F. Hirayama, K. Uekama,
    Serum-resistant Gene Transfer Activity of Mannosylated Dendrimer/α-Cyclodextrin Conjugate (G3),
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 89-93 (2006).
  16. T. Hara, F. Hirayama, H. Arima, Y. Yamaguchi, K. Uekama,
    Prominent Solubilizing Effect of 2-Hydoxypropyl-β-cyclodextrin on a New Thiazolidine Derivative (FPFS-410) with Antidiabetic and Lipid-lowering Activities through Inclusion Complex Formation,
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 135-139 (2006).
  17. T. Hara, H. Arima, F. Hirayama, K. Uekama,
    Enhanced Bioavailability of a New Thiazolidine Derivative FPFS-410, an Antidiabetic and Lipid-lowering Drug, after Oral Administration of Its Hydroxypropyl-β-cyclodextrin Complex to Bile Duct-cannulated Rats,
    J. Pharm. Sci., 95 (8), 1771-1782 (2006).
  18. S. Tavornvipas, F. Hirayama, S. Takeda, H. Arima, K. Uekama,
    Effects of Cyclodextrins on Chemically- and Thermally-induced Unfolding and Aggregation of Lysozyme and Basic Fibroblast Growth Factor,
    J. Pharm. Sci., 95 (12), 2722-2729 (2006).
  19. K. Terao, D. Nakata, H. Fukumi, G. Schmid, H. Arima, F. Hirayama, K. Uekama,
    Enhancement of Oral Bioavailability of Coenzyme Q10 by the Complexation with γ-Cyclodextrin in Healthy Adult Volunteers,
    Nutr. Res., 26 (10), 503-508 (2006).
  20. K. Uekama, F. Hirayama, H. Arima,
    Recent Aspects of Cyclodextrin-based Drug Delivery System,
    J. Incl. Phenom. Macrocycl. Chem., 56 (1-2), 3-8 (2006).
  21. K. Uekama, F. Hirayama, H. Arima,
    Pharmaceutical applications of cyclodextrins and their derivatives, “Cyclodextrins and their complexes”, Ed. by H. Dodziuk, Wiley-VCH Verlag, Weinheim, 2006, pp. 381-422.
  22. 平山文俊,
    “第 9 章　ターゲティング”, “薬学教科書シリーズ第 7 巻　製剤化のサイエンス”, 東京化学同人, 東京, 2006, pp.169-177.